Clinical Trial Update: Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial of USB002 for respiratory distress due to COVID-19 was terminated; results posted in December 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome Adult

Drugs mentioned

• USB002

Snippet

Sponsor: US Biotest, Inc. | Conditions: 2019 Novel Coronavirus Infection, COVID-19 Virus Infection | Phase 2 | Status: TERMINATED | Results posted: 2023-12-01